This limitation necessitates complementary imaging techniques, such as positron emission tomography-computed tomography targeting the prostate-specific membrane antigen (PSMA PET-CT), which is emerging as a potentially more effective method than mpMRI for detecting LNI in patients with intermediate-to-high-risk prostate cancer [16,17,18,19,20], though further data are needed to confirm this. The gene discussed is FOLH1; the disease is prostate carcinoma.